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Abstract
Background—Rotavirus vaccine was introduced into the Extended Program on Immunization in 
Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus 
hospitalization in children < 5 years of age before and after vaccine introduction and assessed 
trend rotavirus genotypes circulating at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna 
(CHU MET).
Methods—From January 2010 to December 2016, we reviewed the logbook admission to 
observe the rate of hospitalization caused by gastroenteritis among 19619 children < 5 years of age 
admitted to hospital In June 2013–Dec 2016. Active rotavirus surveillance was also conducted at 
CHUMET with support from WHO. Rotavirus was detected by EIA from stool specimen of 
children with gastroenteritis eligible surveillance at sentinel site laboratory and rotavirus positive 
specimens were further genotyped at Regional Reference Laboratory by PCR.
Results—Diarrhea hospitalizations decreased after rotavirus vaccine introduction. The median 
proportion of annual hospitalizations due to diarrhea was 26% (range: 31% to 22%) before vaccine 
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for 
Disease Control and Prevention (CDC).
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introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 
2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 
56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 
2016. 21 distinct genotypes were detected in the pre-vaccine period; the most common were 
G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were 
found in 2015; the most common genotype was G2P[4] (n=10; 67%).
Conclusions—Following rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific 
hospitalizations declined dramatically.
Keywords
Rotavirus vaccine; rotavirus; surveillance; genotype
Background
Diarrheal diseases remain one of the most common causes of child mortality in the world, 
with the majority of this burden in developing countries (1). In 2009, the World Health 
Organization (WHO) recommended all countries include rotavirus vaccine in their routine 
immunizations programs (2, 3, 4). In Madagascar, the two-dose oral monovalent human 
rotavirus vaccine, Rotarix(RV1, GSK Biologics), was introduced into the routine Expanded 
Program on Immunization (EPI) in May 2014 with support from WHO and funding from 
Gavi. Madagascar’s vaccine schedule recommends rotavirus vaccine administration to 
infants at 2 and 4 months of age. Rotarix contains a G1P[8] human rotavirus strain and has 
been found to be effective in preventing severe rotavirus disease caused by the vaccine strain 
as well as genotypes not included in the vaccine (5, 6,7).
Laboratory-based rotavirus gastroenteritis sentinel surveillance was initiated in Madagascar 
in June 2013 at one sentinel hospital site in the capital city of Antananarivo. Diarrhea and 
rotavirus surveillance was important for making decisions regarding whether to introduce 
rotavirus vaccine into a country’s routine immunization program and is essential to enable 
monitoring of vaccine impact and for selective pressure of rotavirus genotypes by the 
vaccine. The circulating genotypes can change over seasons and regions. Rotavirus vaccine 
impact evaluations in many countries have shown significant reduction of rotavirus 
hospitalizations since licensure in 2006including: Brazil, US, Panama, Mexico, Austria, 
Australia, Belgium, El Salvador, Rwanda, Ghana (8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18). 
Little is known about rotavirus disease burden and the impact of rotavirus vaccine 
introduction in Madagascar.
The objective of this analysis is to describe the impact of rotavirus vaccine introduction on 
the burden of severe all-cause diarrhea and rotavirus hospitalizations among children ≤59 
months of age admitted to one sentinel surveillance hospital site in Madagascar. We also 
describe the trends in circulating rotavirus genotypes causing severe disease in Madagascar 
among children ≤59 months of age before and after rotavirus vaccine introduction.
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Methods
Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHUMET), an 82 bed public 
referral pediatric hospital located in the capital of Madagascar, primarily serves local 
patients, though some patients come from elsewhere in the country. CHUMET is the only 
rotavirus gastroenteritis surveillance site in Madagascar that reports to the WHO sentinel 
hospital surveillance network.
Retrospective hospital log book review
We reviewed hospital admission logbooks from CHUMET for children <5 years of age 
hospitalized for acute gastroenteritis with or without dehydration from January 1, 2010 to 
December 31, 2016; we compared diarrhea hospitalizations from the pre-vaccine period 
(January 2010 to December 2013 with the post-vaccine period (January 2015 to December 
2016).
Active Rotavirus surveillance
Rotavirus surveillance-eligible stool specimens collected at CHUMET from children ≤59 
months of age were tested for rotavirus antigen by enzyme immunoassay (EIA). Children 
were included if they were admitted with acute gastroenteritis defined as 3 or more watery, 
non-bloody stools within a 24 hour period lasting less than 7 days, and stool was collected 
within 48hours of admission. Surveillance data for this reported was collected from June 
2013 to December 2016; we compared rotavirus prevalence detected by EIA from June 2013 
to April 2014 as the pre-vaccine period with January 2015 to December 2016 as the post-
vaccine period.
Samples submitted to surveillance site laboratory were screened for group A rotavirus using 
EIA prospect TM kit. Rotavirus antigen-positive fecal samples were stored at −20 °C until 
transfer to the regional reference laboratory (RRL) in Medunsa, South Africa for 
confirmation by polymerase chain reaction (PCR) and genotyping.
At the RRL, rotavirus antigen-positive samples were tested for determination of G and P 
types, using semi-nested multiplex PCR method performed with consensus- and genotype-
specific primers. The first-round PCR products were purified; the sequencing was performed 
using consensus primers for the VP7 and VP4 genes and the sequence data were analyzed 
with the bioinformatics software packages. The rotavirus 11 genomic segments were 
separated by polyacrylamide gel electrophoresis (PAGE) to display two major distinctive 
RNA migration patterns. Genotyping results are presented for three periods: June 2013–
April 2014, May–December 2014, and January–December 2015.
Analysis
All analyses were performed and figures generated using Microsoft Excel 2013. The 
Pearson chi square results were calculated using R 3.2.4.
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Results
Retrospective hospital log book review
From January 2010 to December 2013, 12,026 children ≤59 months were admitted to 
hospital; diarrhea hospitalizations represented a median of 26% (range: 31% to 22%) of 
annual hospitalizations during this period (Figure 1). In 2014, the year of rotavirus vaccine 
introduction, 3,362 children ≤59 months were admitted to hospital, of which 25% were due 
to diarrhea. In the years following vaccine introduction, 5821 children were admitted to 
hospital with 16% due to diarrhea, compared with the pre-vaccine median, this is a 36% 
(p<0.001) reduction in the percent diarrhea hospitalizations in the post vaccine period. We 
noted increased diarrhea hospitalizations during two annual seasons: April–June and 
October-November. In 2015 and 2016, two seasonal peaks in diarrhea admissions are 
observable but reduced compared to earlier years (Figure 2). Before rotavirus vaccine 
introduction, 54%, 36%, and 10% of diarrhea hospitalizations included in this analysis were 
among children 0–11 months, 12–23 month, and 24–59 months of age, respectively (Figure 
2); after rotavirus vaccine introduction, this distribution changed to 39%, 42%, and 19% of 
diarrhea hospitalizations, respectively.
Active Rotavirus surveillance
The number of stool specimens tested and EIA rotavirus positive results are shown by month 
from June 2013 to December 2016 in Figure 3; the seasonality and reduction observed in the 
number of stool specimens and rotavirus positivity parallels patterns observed in diarrhea 
hospitalizations (Figure 2). During this period of rotavirus surveillance, we collected and 
analyzed by EIA 203 (30% of all diarrhea admissions) stool specimens before rotavirus 
vaccine introduction and 449 (47% of all diarrhea admissions) stool specimens after 
rotavirus vaccine introduction. The remaining children did not meet the case definition for 
rotavirus or were not able to provide a stool specimen. From June 2013 to April 2014, 
rotavirus was detected in 114 (56%) stool specimens. The proportion of rotavirus positive 
stool specimens was 12% (n=56) in the post vaccine period (2015–2016), a reduction of 
78% (p<0.01). Before vaccine introduction, 67%, 32%, and 1% of all rotavirus detected in 
stool specimens was among children aged 0–11 months, 12–23 months, and 24–59 months. 
In contrast, 48%, 43%, and 9% of all rotavirus detected in stool specimens was among 
children aged 0–11 months, 12–23 months, and 24–59 months after vaccine introduction, 
respectively (Figure 4).
Genotype testing
A total of 195 (69%) rotavirus positive specimens were genotyped at RRL (Table 1). Indeed, 
a limited number of rotavirus positive specimens were further tested for genotype according 
to RRL and WHO recommendations; the rest (n= 317) were not tested. We detected 21 
distinct genotypes during the surveillance period. Before vaccine introduction, 7 different 
genotypes were detected in 80 specimens (Figure 5). The most commonly detected 
genotypes were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). Other 
genotypes were detected in the additional 4 specimens (5%). Of the genotyped specimens 
from the pre-vaccine introduction period, 68% were from children 0–11 months of age 
(Figure 6). During the first eight months after rotavirus vaccine introduction in 2014, 13 
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rotavirus genotypes were detected in 100 specimens. The most common detected genotypes 
were G3P[8] (n=20, 20%) and G9P[6], G9P[8], and G9P[4]P[8] with 9 specimens each. 
There were 9 additional genotypes detected in 53 specimens. In 2015, 6 distinct rotavirus 
genotypes were found in 15 specimens. The most common genotype was G2P[4] (n=10, 
67%). The remaining 5, G3P[8], G9P[4]P[8], G1G3P[4], G1G3P[NT], G3G12P[4]P[8], had 
one positive specimen each. Compared with the genotypes detected pre-vaccination period, 
G1P[8], G3P[NT], G4P[6], G12P[6], and GNTP[8] were not detected in 2015. Of the 
genotyped specimens from 2015, 60% were from children 12–23 months of age.
Discussion
Our analysis of retrospective diarrhea hospitalization admissions and laboratory-confirmed 
rotavirus from a sentinel hospital surveillance site Madagascar following rotavirus vaccine 
introduction showed an important decrease diarrhea hospitalizations and rotavirus positive 
stool specimens, particularly in the 0–11 month age group. Prior to vaccine introduction, we 
identified two annual peaks for diarrhea hospitalizations in April–June and October–
November. In the first 2 years following rotavirus vaccine introduction, a peak in diarrheal 
hospitalizations was observed in June, but with much fewer hospitalizations than the 
previous years and a less distinct peak was observed later in the year. Although the number 
of months of laboratory surveillance from before vaccine introduction are limited, the 
decrease in rotavirus hospitalizations are dramatic and concur with those from diarrhea 
hospital admissions. To the best of our knowledge, this is the first published description of 
severe diarrhea and rotavirus disease burden in the pre- and post-rotavirus vaccine 
introduction in Madagascar.
As rotavirus vaccine was introduced to Madagascar’s national immunization schedule in 
2014, we expected a reduction in diarrhea and rotavirus illness among children 0–11 months 
of age in 2015 and 2016, since this cohort was eligible for vaccination. We also expected a 
reduction in diarrhea and rotavirus illness children 12–23 months of age in 2016, since they 
would have been eligible for vaccination as infants the previous year. The nation-wide 
coverage of rotavirus vaccination estimated by WHO/UNICEF was 39% in 2014 and 69% in 
2015(19). We observed the greatest reduction in diarrhea and rotavirus illness in age groups 
targeted for rotavirus vaccination. These findings are similar to several other countries that 
have introduced rotavirus vaccine, including Ghana, Rwanda, Malawi, South Africa, Brazil, 
Mexico, Panama and El Salvador (8, 9, 11, 12, 13, 17, 18, 19, 21, 22, 23, 23). Reductions in 
diarrhea and rotavirus in age groups not eligible for vaccination, have also been reported by 
several high-income and middle-income countries, including the USA, Australia, Austria, 
and El Salvador (10, 11, 17, 25, 26, 27). Rwanda showed also indirect protection of groups 
not eligible for vaccination two years only after introduction, although indirect effects were 
not found in Zambia and South Africa (17, 22, 29). In Madagascar, there were very few 
hospitalized children ages 24–59 months and we did not observed a reduction in diarrhea 
hospitalizations or rotavirus stools in the 12–23 and 24–59 month old age group. This cohort 
was not targeted for vaccination during this surveillance period.
Before vaccine introduction, the most common genotypes were G1P[8], G2P[4], andG3P[8], 
which is similar to findings from the USA and the majority of the countries in Europe (29, 
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30, 31). In 2015, G2P[4] became the most common genotype in Madagascar. Rotarix has 
been demonstrated to have high levels of protection against homotypic (G1P[8]) and 
partially heterotypic G1 strains or P[8]-expressing strains; many studies have also found 
high levels of protection against heterotypic strains ( 35,36, 37, 38, 39, 40, 41, 42, 43, 44, 
45). While this analysis has limited data following vaccine introduction, the rotavirus 
genotype G1P[8] was not observed after vaccine introduction and genotype G3P[8] also 
decreased in first year after vaccine implementation. Ongoing surveillance of circulating 
rotavirus genotypes is important to observe for selective pressure, which could lead to 
diminished vaccine effectiveness.
This descriptive analysis has several limitations. First, during the surveillance period, not all 
children hospitalized for diarrhea were tested for rotavirus (758/2168); as decisions about 
stool testing were made based on the rotavirus case definition, we do not believe this will 
bias the results. Second, there was only one surveillance sentinel site in the country located 
in the capital so our results may not be representative of all children in Madagascar. Third, 
laboratory sentinel hospital surveillance was initiated only 11 months prior to rotavirus 
vaccine introduction, consequently we are limited in the information we have about rotavirus 
disease burden prior to vaccine introduction. Additionally, 11 months of surveillance is an 
imperfect comparison for 12 month periods; nonetheless, we did observe significant 
reductions in rotavirus positive stools. Finally, data about molecular epidemiology of 
rotavirus are limited, making it difficult to draw conclusions about the post-vaccine 
introduction situation in Madagascar.
In summary, hospital admissions for diarrhea and rotavirus declined during the first two 
years after introduction of rotavirus vaccine in Madagascar among groups targeted for 
vaccination. These findings are similar to those reported by other countries that had 
previously introduced rotavirus vaccine. These promising results may be built upon as 
Madagascar works to improve routine vaccination coverage in future years and as the 
cohorts of vaccine-eligible children ages.
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Figure 1. 
Number of all diarrhea hospitalizations and total hospital admissions, and percent of total 
hospital admissions attributed to diarrhea among children ≤59 months by year 2010–2016, 
Madagascar.
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Figure 2. 
Total and age group-specific number of diarrhea hospitalizations among children ≤59 
months of age at sentinel hospital from January 2010 to December 2016, Madagascar.
Rahajamanana et al. Page 11
Vaccine. Author manuscript; available in PMC 2019 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Number of rotavirus positive stool samples among children ≤59 months of age by month 
from June 2013 to December 2016, Madagascar.
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Figure 4. 
Percent of total rotavirus positive samples by age group before and after rotavirus vaccine 
introduction, Madagascar.
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Figure 5. 
Rotavirus genotype distribution by year, Madagascar.
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Figure 6. 
Rotavirus genotype according to age groups during pre-vaccine introduction period, in Jun–
Dec 2014 and in 2015, Madagascar.
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